KR102755259B1 - Sting 효능제로서의 벤조티오펜 및 관련 화합물 - Google Patents
Sting 효능제로서의 벤조티오펜 및 관련 화합물 Download PDFInfo
- Publication number
- KR102755259B1 KR102755259B1 KR1020207031242A KR20207031242A KR102755259B1 KR 102755259 B1 KR102755259 B1 KR 102755259B1 KR 1020207031242 A KR1020207031242 A KR 1020207031242A KR 20207031242 A KR20207031242 A KR 20207031242A KR 102755259 B1 KR102755259 B1 KR 102755259B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- compound
- independently selected
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652018P | 2018-04-03 | 2018-04-03 | |
| US62/652,018 | 2018-04-03 | ||
| US201962809956P | 2019-02-25 | 2019-02-25 | |
| US62/809,956 | 2019-02-25 | ||
| PCT/US2019/025088 WO2019195124A1 (en) | 2018-04-03 | 2019-04-01 | Benzothiophenes and related compounds as sting agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200139203A KR20200139203A (ko) | 2020-12-11 |
| KR102755259B1 true KR102755259B1 (ko) | 2025-01-15 |
Family
ID=66175500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207031242A Active KR102755259B1 (ko) | 2018-04-03 | 2019-04-01 | Sting 효능제로서의 벤조티오펜 및 관련 화합물 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10793557B2 (https=) |
| EP (1) | EP3774764A1 (https=) |
| JP (1) | JP7326319B2 (https=) |
| KR (1) | KR102755259B1 (https=) |
| CN (1) | CN111971277B (https=) |
| AU (1) | AU2019248545B2 (https=) |
| CA (1) | CA3095646A1 (https=) |
| MA (1) | MA52189A (https=) |
| MX (1) | MX2020010407A (https=) |
| TW (1) | TWI793294B (https=) |
| WO (1) | WO2019195124A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7270608B2 (ja) | 2017-08-31 | 2023-05-10 | エフ－スター・セラピューティクス・インコーポレイテッド | 化合物、組成物、及び疾患の治療方法 |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CN111393405B (zh) * | 2019-01-02 | 2022-11-25 | 中国科学院上海药物研究所 | 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用 |
| EP3964504A4 (en) * | 2019-04-30 | 2022-12-28 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | AMINOPYRIMIDINE COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| CA3149482A1 (en) | 2019-08-02 | 2021-02-11 | Mersana Therapeutics, Inc. | Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer |
| CN112724127B (zh) * | 2019-10-28 | 2023-02-17 | 中国科学院上海药物研究所 | 五元杂环氧代羧酸类化合物及其医药用途 |
| WO2021113679A1 (en) * | 2019-12-06 | 2021-06-10 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| CN113087668B (zh) * | 2019-12-23 | 2022-11-04 | 中国科学院上海药物研究所 | 一类苯并咪唑二聚体、其制备方法及用途 |
| CN113248475B (zh) * | 2020-02-11 | 2023-03-17 | 中国科学院上海药物研究所 | 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途 |
| WO2021202984A1 (en) | 2020-04-02 | 2021-10-07 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| CN115996756A (zh) | 2020-05-08 | 2023-04-21 | 博尔特生物治疗药物有限公司 | 弹性蛋白酶底物肽连接子免疫缀合物及其用途 |
| CN113861161A (zh) * | 2020-06-30 | 2021-12-31 | 上海海和药物研究开发股份有限公司 | 一种芳基并芳杂环衍生物及其制备方法和用途 |
| EP4208260A1 (en) * | 2020-09-02 | 2023-07-12 | The Scripps Research Institute | Agonists of stimulator of interferon genes sting |
| US11964978B2 (en) * | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
| JP2024511832A (ja) * | 2021-03-30 | 2024-03-15 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッド | Ｓｔｉｎｇアゴニストとして有用な新規化合物およびその使用 |
| CN113429384B (zh) * | 2021-05-12 | 2022-04-08 | 中山大学附属第五医院 | 一类干扰素基因刺激因子靶向的放射性pet显像剂 |
| CN115772154B (zh) * | 2021-09-08 | 2024-04-30 | 上海交通大学 | 一类含有氘取代的苯并噻吩类衍生物及其制备与用途 |
| CN114213315A (zh) * | 2021-12-31 | 2022-03-22 | 上海陶术生物科技有限公司 | 含氮杂环类化合物及其中间体的合成方法 |
| US20250099392A1 (en) * | 2022-01-20 | 2025-03-27 | Ohio State Innovation Foundation | Compositions comprising lipid compounds and methods of making and use thereof |
| CN119212984A (zh) * | 2022-04-25 | 2024-12-27 | 密歇根大学董事会 | Sting激动剂、制剂及其用途 |
| AU2023283720A1 (en) * | 2022-06-06 | 2025-01-02 | Sutro Biopharma, Inc. | Sting agonist compounds |
| WO2024032782A1 (en) * | 2022-08-12 | 2024-02-15 | Jacobio Pharmaceuticals Co.Ltd. | Vaccine adjuvants and uses thereof |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| EP4671250A1 (en) * | 2023-02-24 | 2025-12-31 | Shenzhen Genuine Biotechnology Co., Ltd. | Tricyclic Sting Agonist and its Use |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| CN116332903B (zh) * | 2023-03-29 | 2024-11-12 | 中国药科大学 | 一种具有苯并[b]硒吩结构的二聚化合物及其用途 |
| CN116354922B (zh) * | 2023-03-31 | 2025-04-25 | 药康众拓(江苏)医药科技有限公司 | 氘代苯并噻吩类化合物及其药物组合物和用途 |
| WO2025007743A1 (en) * | 2023-07-04 | 2025-01-09 | Primelink Biotherapeutics (Shenzhen) Co., Ltd. | Sting agonists and uses thereof |
| WO2025081077A1 (en) * | 2023-10-13 | 2025-04-17 | University Of Rhode Island Board Of Trustees | Targeted intracellular delivery of dimeric msa stinga by two phlip® peptides |
| CN117402139B (zh) * | 2023-10-18 | 2026-01-27 | 南通大学 | Sting激动剂msa-2的锰盐合成和肿瘤治疗应用 |
| WO2026055185A1 (en) | 2024-09-04 | 2026-03-12 | Bolt Biotherapeutics, Inc. | Sting agonist immunoconjugates and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015077354A1 (en) | 2013-11-19 | 2015-05-28 | The University Of Chicago | Use of sting agonist as cancer treatment |
| WO2018067423A1 (en) | 2016-10-04 | 2018-04-12 | Merck Sharp & Dohme Corp. | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB532822A (en) | 1939-08-11 | 1941-01-31 | John David Kendall | Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters |
| US4342689A (en) | 1980-04-28 | 1982-08-03 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| US4299769A (en) | 1980-04-28 | 1981-11-10 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| US4342690A (en) | 1980-04-28 | 1982-08-03 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| US4342691A (en) | 1980-04-28 | 1982-08-03 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| EP0146243A1 (en) | 1983-10-31 | 1985-06-26 | Merck Frosst Canada Inc. | Lipoxygenase inhibitors |
| ATE128135T1 (de) | 1988-07-11 | 1995-10-15 | Akzo Nobel Nv | Pyridazinon-derivate. |
| US5559127A (en) | 1992-10-14 | 1996-09-24 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5569655A (en) * | 1993-09-14 | 1996-10-29 | Sterling Winthrop Inc. | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof |
| EP1086091A4 (en) | 1998-06-03 | 2001-10-10 | Merck & Co Inc | INTEGRASE HIV INHIBITORS |
| US6262055B1 (en) | 1998-06-03 | 2001-07-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| AU2001248701A1 (en) | 2000-03-24 | 2001-10-03 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP1368458A2 (en) | 2001-02-26 | 2003-12-10 | Pharma Pacific Pty. Ltd. | Interferon-alpha induced gene |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| AU2004268012B2 (en) | 2003-09-02 | 2008-11-20 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| EP1729781B1 (en) | 2004-03-15 | 2012-10-24 | Karaolis, David K. R. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| US8664255B2 (en) | 2008-10-20 | 2014-03-04 | The Texas A&M University System | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2012068702A1 (zh) | 2010-11-23 | 2012-05-31 | 中国医学科学院医药生物技术研究所 | 苯并五元不饱和杂环类化合物及其制备方法 |
| JP5887947B2 (ja) | 2011-03-28 | 2016-03-16 | ソニー株式会社 | 透明導電膜、ヒータ、タッチパネル、太陽電池、有機ｅｌ装置、液晶装置および電子ペーパ |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| CN104507538B (zh) | 2012-06-08 | 2018-04-06 | 艾杜罗生物科技公司 | 癌症免疫疗法的组合物和方法 |
| CN103840995B (zh) | 2012-11-26 | 2017-10-24 | 华为技术有限公司 | Ip报文处理方法、装置及网络系统 |
| PL2931738T3 (pl) | 2012-12-13 | 2019-07-31 | Aduro Biotech, Inc. | Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| PT2934598T (pt) | 2012-12-19 | 2018-07-24 | Univ Texas | Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| KR102322425B1 (ko) * | 2013-07-30 | 2021-11-05 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체 |
| EP3027227A4 (en) | 2013-07-31 | 2018-05-23 | Memorial Sloan Kettering Cancer Center | Sting crystals and modulators |
| US10092644B2 (en) | 2013-11-22 | 2018-10-09 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| CN103908468B (zh) | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
| PE20170198A1 (es) | 2014-06-04 | 2017-04-08 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting |
| WO2015189117A1 (de) | 2014-06-12 | 2015-12-17 | Bayer Pharma Aktiengesellschaft | Heterobicyclisch substituierte 4-oxobutansäure-derivate und ihre verwendung |
| EP3546473B1 (en) | 2014-12-16 | 2025-12-10 | Kayla Therapeutics | Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| WO2016096577A1 (en) | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| WO2016100261A2 (en) | 2014-12-17 | 2016-06-23 | Lipogen Llc | Method of treating cancer with cgamp or cgasmp |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| TW201717968A (zh) | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物 |
| US10844051B2 (en) | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
| CR20180101A (es) | 2015-08-13 | 2018-04-12 | Merck Sharp & Dohme | Compuestos di-nucleóticos cíclicos como agonistas de sting |
| US9809597B2 (en) | 2015-08-20 | 2017-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy |
| CA3002236A1 (en) | 2015-10-28 | 2017-05-04 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| TWI704154B (zh) | 2015-12-03 | 2020-09-11 | 英商葛蘭素史克智慧財產發展有限公司 | 新穎化合物 |
| EP3386536A4 (en) | 2015-12-07 | 2019-07-31 | Opi Vi- IP Holdco LLC | COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF |
| WO2017123657A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| RS67188B1 (sr) | 2016-01-11 | 2025-10-31 | Innate Tumor Immunity Inc | Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer |
| SG10201912074PA (en) | 2016-03-18 | 2020-02-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| HRP20220936T1 (hr) | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterociklički amidi korisni kao modulatori proteina |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| CA3026211A1 (en) | 2016-06-13 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as inhibitors of dnmt1 |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
-
2019
- 2019-04-01 US US16/372,103 patent/US10793557B2/en active Active
- 2019-04-01 EP EP19717660.5A patent/EP3774764A1/en active Pending
- 2019-04-01 MX MX2020010407A patent/MX2020010407A/es unknown
- 2019-04-01 WO PCT/US2019/025088 patent/WO2019195124A1/en not_active Ceased
- 2019-04-01 AU AU2019248545A patent/AU2019248545B2/en active Active
- 2019-04-01 CA CA3095646A patent/CA3095646A1/en active Pending
- 2019-04-01 KR KR1020207031242A patent/KR102755259B1/ko active Active
- 2019-04-01 MA MA052189A patent/MA52189A/fr unknown
- 2019-04-01 CN CN201980024834.7A patent/CN111971277B/zh active Active
- 2019-04-01 JP JP2020553626A patent/JP7326319B2/ja active Active
- 2019-04-01 TW TW108111487A patent/TWI793294B/zh not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015077354A1 (en) | 2013-11-19 | 2015-05-28 | The University Of Chicago | Use of sting agonist as cancer treatment |
| WO2018067423A1 (en) | 2016-10-04 | 2018-04-12 | Merck Sharp & Dohme Corp. | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020132585A (ru) | 2022-05-06 |
| BR112020020085A2 (pt) | 2021-02-17 |
| JP7326319B2 (ja) | 2023-08-15 |
| US10793557B2 (en) | 2020-10-06 |
| CN111971277A (zh) | 2020-11-20 |
| TW202003509A (zh) | 2020-01-16 |
| AU2019248545A1 (en) | 2020-10-15 |
| US20190300513A1 (en) | 2019-10-03 |
| CA3095646A1 (en) | 2019-10-10 |
| AU2019248545B2 (en) | 2022-08-11 |
| EP3774764A1 (en) | 2021-02-17 |
| MX2020010407A (es) | 2020-10-22 |
| JP2021520345A (ja) | 2021-08-19 |
| BR112020020085A8 (pt) | 2023-04-11 |
| MA52189A (fr) | 2021-02-17 |
| TWI793294B (zh) | 2023-02-21 |
| WO2019195124A1 (en) | 2019-10-10 |
| CN111971277B (zh) | 2023-06-06 |
| KR20200139203A (ko) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102755259B1 (ko) | Sting 효능제로서의 벤조티오펜 및 관련 화합물 | |
| KR102312721B1 (ko) | STING 효능제로서의 벤조[b]티오펜 화합물 | |
| CN108137641B (zh) | 作为sting激动剂的环状双核苷酸化合物 | |
| EP3774765A1 (en) | Aza-benzothiophene compounds as sting agonists | |
| CN111630036B (zh) | 氧代吖啶基乙酸衍生物及其使用方法 | |
| EA030811B1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| RU2806274C2 (ru) | Бензотиофены и родственные соединения в качестве агонистов STING | |
| JP2022533194A (ja) | ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法 | |
| BR112020020085B1 (pt) | Composto, composição farmacêutica, e, usos de um composto, ou um sal farmaceuticamente aceitável do mesmo, e de uma composição farmacêutica | |
| HK40005319B (en) | Benzo[b]thiophene compounds as sting agonists | |
| EA044594B1 (ru) | Производные оксоакридинилуксусной кислоты и способы применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20201029 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220216 Comment text: Request for Examination of Application |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20220901 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240404 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241217 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250110 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250110 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |